A phase III study (TROPION-Lung08, NCT05215340) is also evaluating the efficacy of first-line Dato-DXd plus pembrolizumab versus pembrolizumab monotherapy in patients with advanced/metastatic NSCLC without actionable genomic alterations and with a PD-L1 tumor proportion score ≥ 50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.